[go: up one dir, main page]

US3331752A - Determination of dehydrogenase - Google Patents

Determination of dehydrogenase Download PDF

Info

Publication number
US3331752A
US3331752A US555690A US55569066A US3331752A US 3331752 A US3331752 A US 3331752A US 555690 A US555690 A US 555690A US 55569066 A US55569066 A US 55569066A US 3331752 A US3331752 A US 3331752A
Authority
US
United States
Prior art keywords
phenanthroline
nicotinamide
acid
enzyme
adenine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
US555690A
Inventor
Jr Jacob Struck
John K Inman
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ortho Pharmaceutical Corp
Original Assignee
Ortho Pharmaceutical Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ortho Pharmaceutical Corp filed Critical Ortho Pharmaceutical Corp
Priority to US555690A priority Critical patent/US3331752A/en
Application granted granted Critical
Publication of US3331752A publication Critical patent/US3331752A/en
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/26—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving oxidoreductase
    • C12Q1/32—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving oxidoreductase involving dehydrogenase

Definitions

  • ABSTRACT OF THE DISCLOSURE Concentration of nicotinamide-adenine nucleotide de pendent enzymes determined in a body fluid by incubating said fluid in presence of reduced substrate, an oxidised coenzyme, a divalent cation and a reducible color developing metal chelate.
  • the present invention relates to a method of determining nicotinamide-adenine nucleotide dependent enzymes in body fluids.
  • Nicotinamide-adenine nucleotide dependent enzymes are found in almost all body tissues and fluids. It is known that the alteration in the normal concentration of a constituent of blood serum is very commonly indicative of disease. Recently, tests for enzymes in body tissues and fluids have found application in clinical biochemistry. Where applied to a specific body tissue, an abnormally high enzyme level in the tissue frequently is a sign of disease in that tissue. Although an increase in the enzyme level of body fluids does not pinpoint disease in a specific body tissue, it does serve as an aid to diagnosis which is made in conjunction with other tests and clinical observations.
  • the circulating plasma levels of intracellular enzymes are probably governed by several mechanisms. Normal levels are believed to arise from a balance between release from body cells and excretion or inactivation. During disease, however, a considerable increase in circulating levels may occur as a result of the alteration of cell membrane permeability with the consequent release of intracellular enzymes into the extracellular fluid. Severe tissue damage accompanied by necrosis may produce a similar efiect on the level of circulating enzymes.
  • nicotinamide-adenine nucleotide dependent enzymes More than one hundred nicotinamide-adenine nucleotide dependent enzymes have been identified. Representative of such enzymes are L-malate dehydrogenase, L- lactate dehydrogenase, u-hydroxybutyrate dehydrogenase, D-sorbitol dehydrogenase, isocitric dehydrogenase and alcohol dehydrogenase.
  • An abnormally elevated serum level of lactate dehydrogenase occurs in cases of myocardial infarction. Increased lactate dehydrogenase activity has also been reported in acute liver diseases, muscular dystrophy, neoplastic diseases, pernicious anemia and renal diseases and increased isocitrate dehydrogenase activity is a good indication of liver damage.
  • Enzyme catalyzed oxidation-reduction reactions which require the participation of nicotinamide-adenine nucleoreduced substrate Since these reactions are reversible, valid measurement of enzyme activity may be performed regardless of the direction in which a specific reaction is carried out.
  • the initial rate of the reaction is directly proportional to the concentration of the enzyme.
  • an acidic solution of a readily reducible metal chelate compound is'added to a reaction mixture in which a reduced nicotinamideadenine nucleotide has been allowed to accumulate under standardized conditions as a product of enzyme catalyzed reaction between reduced substrate and oxidized coenzyme.
  • the enzyme reaction is stopped by reduction of pH and the reduced nicotinamide-adenine nucleotide coenzyme reacts with the oxidized metal chelate to form a reduced metal chelate compound.
  • the oxidized metal chelate chosen is one which has an adsorption spectrum which differs appreciably from the adsorption spectrum of the reduced metal chelate, thus providing a simple colorimetric method for the determination of enzyme activity.
  • the oxidized nicotinamide-adenine nucleotide coenzyme which is reduced may be nicotinamide-adenine dinucleotide, nicotinamide-adenine dinucleotide phosphate or suitable derivatives of these compounds.
  • the choice of the reduced substrate portion of the reaction mixture is dependent upon the nicotinamide-adenine nucleotide dependent enzyme which is being tested for.
  • reduced substrate is meant the substance which is acted upon by the enzyme under test.
  • substrates include lactic acid and lactic acid salts, malic acid and malic acid salts, isocitric acid and isocitric acid salts, a-hydroxybutyric acid and uhydroxybutyric acid salts, sorbital and ethanol.
  • the enzyme catalyzed reaction is carried out in a solution which is buflered to a pH within a range which gives measurable enzyme activity.
  • the pH range in which the activity of lactate dehydrogenase is most marked is between about 7.5 and about 10.5, preferably about 10.0.
  • the reaction is permitted to proceed until a measurable amount of the reduced nicotinamideadenine nucleotide coenzyme is formed. This will be between about 5 to about 20 minutes at a temperature of about 37 C.
  • the reaction is then stopped by acidifying the reaction mixture to reduce to pH to a range of from about 2.8 to about 5.0, preferably about 3.2.
  • the solution used to stop the reaction may contain a color developing metal chelate, or the color developing metal chelate may be added after the reaction is stopped.
  • the chelate system used should be such that 1) the oxidized system will be reduced by the reduced nicotinamide-adenine dinucleotide, and (2) there be a significant diiference in some property, such as light absorption, between the oxidized and reduced chelate.
  • Color developing metal chelates which have been found to be useful include ferri chelates of 1,10-phenanthroline and sulfonated 4,7-diphenyl-l,lO-phenanthroline, cupric chelates of 2,9-dimethyl-1,IO-phenanthroline and sulfonated 2,9-dimethyl-4,7-diphenyl-1,10-phenanthroline.
  • NADH reduced nicotinamide-adenine-dinucleotide
  • NAD is also known as coenzyme I and NADP is also known as coenzyme II.
  • Lactate dehydrogenase Reagent A is prepared having the following composition:
  • Reagent B is prepared having the following composition:
  • reaction mixtures are kept at 37 C. for 12 minutes.
  • the optical density of each of the reaction mixtures is read using a spectrophotometer set at wavelength 455 mg.
  • lactate dehydrogenase per milliliter The units of lactate dehydrogenase per milliliter are read from a calibration curve prepared in accordance with the procedure set out in Example II.
  • EXAMPLE II Preparation of calibrati n curve for use in lactate dehydrogenase activity determination
  • a calibration curve must be prepared using known concentrations of enzyme. Enzyme activities are expressed in terms of a lactate dehydrogenase unit defined as the amount of enzyme which catalyzes the conversion 'of one micromole NAD'to one micromole of NADH per 4 minute during the initial stage of the reaction carried out in the presence of very high concentrations of DL- lactate and NAD at pH 10.0 and 25 C. in a 0.1 M glycine-sodium glycinate butter.
  • a series of solutions of known concentrations of lactate dehydrogenase activity are prepared from a lyophilized preparation of dialyzed human plasma having an elevated lactate dehydrogenase activity. Each of the solutions is assayed according to the following procedure.-
  • 0.10 ml. of enzyme solution is mixed with 5.0 ml. of buffered substrate solution having a temperature of 37 C.
  • the buffered substrate solution contains 0.15 M DL-lactate, 0.0021 M NAD, and 0.1 M epsilon- Enzyme concentration, Measured units per ml.: absorbance EXAMPLE III Malate dehydrogenase
  • 0.2 ml. of enzyme solution is mixed with 5.0 ml. of buffered substrate solution having a temperature of 37 C.
  • the buffered substrate solution contains 0.10 M DL-malate, 0.002 M NAD and 0.10 M epsilonaminocaproate buffer.
  • the substrate solution has a pH of 10.0.
  • the mixture is incubated for 12 minutes at 37 C.
  • the NADH formed is determined by mixing 1.0 ml. of the incubation mixture with 4.0 ml. of solution containing 0.25 M acetic acid, 0.175 M sodium acetate, 0.115 N sulfuric acid, 0.0005 M cupric sulfate and 0.002 M 2,9- dimethyl-l,10-phenanthroline. After fifteen minutes, the absorbance of the solution is measured at 455 m against a blank prepared in an identical manner, except that the NAD is omitted from the buffered substrate. solution.
  • EXAMPLE V Isocz'trate delzydrogenase At zero time 0.2 ml. of enzyme solution is mixed with 2.8 ml. of buffered substrate solution containing 0.0035 M trisodium isocitrate, 0.15 M sodium chloride, 0.0017 M manganese chloride, 0.0018 M NADP and 0.054 M tris (hydroxymethyl)-aminomethane. The pH of the solution is 7.5. The mixture is incubated at 37 C. for 12 minutes. The NADPI-I formed is determined by the addition of 3.0 ml.
  • Relative concentration Absorbance homogenate at 455 m While the foregoing examples illustrate the use of the cupric chelate of 2,9-dimethyl-1,10-phenanthroline as the reducible color developing metal chelate, the reduction of other reducible color developing metal chelates 'by reduced nicotinamide-adenine 'dinucleotide (NADH are illustrated in the following examples:
  • Example VI A 0.2 ml. aliquot of an aqueos solution 0.01 M in the ferric chelate of 1,10-phenanthroline is added to 4.5 ml. of 0.5 M acetate bufier, pH 4.0. This solution is mixed with 0.5 ml. of a solution containing 1.74 M NADH and the absorbance of the resulting mixture is recorded at 510 my, the absorption maximum of ferrous 1,10-phenanthroline. A maximum absorbance of 0.351 was recorded after 30 min.
  • Example VIII A 0.2 ml. aliquot of an aqueous solution 0.01 M in the ferric chelate of sulfonated 4,7-diphenyl-1,10-phenanthroline was added to 4.5 ml. of 0.5 M acetate butter, pH 4.0. This solution was mixed with 0.5 ml. of a solution containing 1.74 10- M NADH and the absorbance of the resulting mixture was recorded at 525 m the absorption maximum of the ferrous chelate of sulfonated 4,7-diphenyl-1,10-phenanthroline. A maximum absorbance of 0.611 was recorded after 24 min.
  • Example IX A 0.2 ml. aliquot of an aqueous solution 0.01M in the cupric chelate of 2,9-dimethyl-4,7-diphenyl-1,10-phenanthroline is added to 4.5 ml. of 0.5 M acetate bufiier, pH 4.0. This solution is mixed with 0.5 ml. of a solution containing 1.74 10- M NADH and the absorbance of the resulting mixture is recorded at 480 my, the absorption maximum of the cu-prous chelate of 2,9-dimethyl-4,7-diphenyl-l,10-phenanthroline. A maximum absorbance of 0.400 is recorded after 15 min.
  • a method of determining the concentration in body fluid of nicotinamide-adenine nucleotide dependent enzymes which comprises incubating in a small volume of body fluid a buffered reduced substrate selected from the group consisting of lactic acid and lactic acid salts, malic acid and malic acid salts, a-hydroxybutyric acid and ahydroxybutyric acid salts, sorbitol, isocitric acid and isocitric acid salts and ethanol, and an oxidized coenzyme selected from the group consisting of nicotinamide-adenine dinucleotide and nicotinamide-adenine dinucleotide phosphate and a divalent cation, reducing the pH of the reaction mixture to a pH between about 2.8 and about 5.0 and adding a reducible color developing metal chelate selected from the group consisting of ferri chelates of 1,10-phenanthroline, 4,7-di'phenyl- 1,10-phenanthroline and sulf

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Physics & Mathematics (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Description

United States Patent Oflice 3,331,752 Patented July 18, 196? 3,331,752 DETERMINATION OF DEHYDROGENASE Jacob Struck, in, Flemingtou, N.J., and John K. Inman,
Bethesda, Md, assignors to Ortho Pharmaceutical Corporation, a corporation of New Jersey No Drawing. Filed June 7, 1966, Ser. No. 555,690 5 Claims. (Cl. 195103.5)
ABSTRACT OF THE DISCLOSURE Concentration of nicotinamide-adenine nucleotide de pendent enzymes determined in a body fluid by incubating said fluid in presence of reduced substrate, an oxidised coenzyme, a divalent cation and a reducible color developing metal chelate.
The present application is a continuation-in-part of our patent application S.N. 360,420, filed Apr. 16, 1964, and now abandoned.
The present invention relates to a method of determining nicotinamide-adenine nucleotide dependent enzymes in body fluids.
Nicotinamide-adenine nucleotide dependent enzymes are found in almost all body tissues and fluids. It is known that the alteration in the normal concentration of a constituent of blood serum is very commonly indicative of disease. Recently, tests for enzymes in body tissues and fluids have found application in clinical biochemistry. Where applied to a specific body tissue, an abnormally high enzyme level in the tissue frequently is a sign of disease in that tissue. Although an increase in the enzyme level of body fluids does not pinpoint disease in a specific body tissue, it does serve as an aid to diagnosis which is made in conjunction with other tests and clinical observations.
Diagnostic enzyme tests are usually performed with blood serum since this body fluid is easily obtained, but enzyme assays of other body fluids are also useful.
In the normal individual, the circulating plasma levels of intracellular enzymes are probably governed by several mechanisms. Normal levels are believed to arise from a balance between release from body cells and excretion or inactivation. During disease, however, a considerable increase in circulating levels may occur as a result of the alteration of cell membrane permeability with the consequent release of intracellular enzymes into the extracellular fluid. Severe tissue damage accompanied by necrosis may produce a similar efiect on the level of circulating enzymes.
At the present time, there is considerable'speculation with regard to the origin and fate of serum enzymes. Although the factors which regulate serum enzyme levels are only poorly understood, this lack of knowledge has not impeded the purely empirical development of diag nostic enzyme tests.
More than one hundred nicotinamide-adenine nucleotide dependent enzymes have been identified. Representative of such enzymes are L-malate dehydrogenase, L- lactate dehydrogenase, u-hydroxybutyrate dehydrogenase, D-sorbitol dehydrogenase, isocitric dehydrogenase and alcohol dehydrogenase. An abnormally elevated serum level of lactate dehydrogenase occurs in cases of myocardial infarction. Increased lactate dehydrogenase activity has also been reported in acute liver diseases, muscular dystrophy, neoplastic diseases, pernicious anemia and renal diseases and increased isocitrate dehydrogenase activity is a good indication of liver damage.
Enzyme catalyzed oxidation-reduction reactions which require the participation of nicotinamide-adenine nucleoreduced substrate Since these reactions are reversible, valid measurement of enzyme activity may be performed regardless of the direction in which a specific reaction is carried out. The initial rate of the reaction is directly proportional to the concentration of the enzyme.
It is an object of the present invention to provide a simple colorimetric test for the determination of nicotinamide-adenine nucleotide dependent enzymes in body fluids.
Other objects and advantages of this invention will become apparent from the following detailed description.
According to the present method, an acidic solution of a readily reducible metal chelate compound is'added to a reaction mixture in which a reduced nicotinamideadenine nucleotide has been allowed to accumulate under standardized conditions as a product of enzyme catalyzed reaction between reduced substrate and oxidized coenzyme. The enzyme reaction is stopped by reduction of pH and the reduced nicotinamide-adenine nucleotide coenzyme reacts with the oxidized metal chelate to form a reduced metal chelate compound. The oxidized metal chelate chosen is one which has an adsorption spectrum which differs appreciably from the adsorption spectrum of the reduced metal chelate, thus providing a simple colorimetric method for the determination of enzyme activity.
The oxidized nicotinamide-adenine nucleotide coenzyme which is reduced may be nicotinamide-adenine dinucleotide, nicotinamide-adenine dinucleotide phosphate or suitable derivatives of these compounds. The choice of the reduced substrate portion of the reaction mixture is dependent upon the nicotinamide-adenine nucleotide dependent enzyme which is being tested for. By reduced substrate is meant the substance which is acted upon by the enzyme under test. Such substrates include lactic acid and lactic acid salts, malic acid and malic acid salts, isocitric acid and isocitric acid salts, a-hydroxybutyric acid and uhydroxybutyric acid salts, sorbital and ethanol.
The enzyme catalyzed reaction is carried out in a solution which is buflered to a pH within a range which gives measurable enzyme activity. For example, the pH range in which the activity of lactate dehydrogenase is most marked is between about 7.5 and about 10.5, preferably about 10.0. The reaction is permitted to proceed until a measurable amount of the reduced nicotinamideadenine nucleotide coenzyme is formed. This will be between about 5 to about 20 minutes at a temperature of about 37 C. The reaction is then stopped by acidifying the reaction mixture to reduce to pH to a range of from about 2.8 to about 5.0, preferably about 3.2. The solution used to stop the reaction may contain a color developing metal chelate, or the color developing metal chelate may be added after the reaction is stopped.
The chelate system used should be such that 1) the oxidized system will be reduced by the reduced nicotinamide-adenine dinucleotide, and (2) there be a significant diiference in some property, such as light absorption, between the oxidized and reduced chelate.
Color developing metal chelates which have been found to be useful include ferri chelates of 1,10-phenanthroline and sulfonated 4,7-diphenyl-l,lO-phenanthroline, cupric chelates of 2,9-dimethyl-1,IO-phenanthroline and sulfonated 2,9-dimethyl-4,7-diphenyl-1,10-phenanthroline.
The formation of reduced nicotinamide-adenine-dinucleotide (NADH is illustrated by the following equations wherein nicotinamide-adenine nucleotide dependent enzymes catalyze the reversible oxidation of the substrate oxidized reduced coenzyme in the presence of nicotinamide-adenine dinucleotide (NAD):
(1) Malate dehydrogenase L-'-malate-}NAD. oxalacetate+NADH (2) Alcohol dehydrogenase ethanol+NAD:acetaldehyde-{NADH (3) Lactate dehydrogenase L-lactate+NAD:pyruvate+NADH Isocitr-ate dehydrogenase is representative of an enzyme which'requires the coenzyme nicotinamide-adenine dinucleotide phosphate (NADP) to carry out the oxidation reaction. In addition, the enzyme is activated by certain divalent cations. The most effective divalent cation tested is the manganous ion (Mn++). The equation for this reaction is as follows:
(+)-isocitrate N ADP a-ketoglutarate C: NADPH:
NAD is also known as coenzyme I and NADP is also known as coenzyme II.
The following examples are intended to illustrate, but not to limit, the scope of the present invention:
EXAMPLE I Lactate dehydrogenase Reagent A is prepared having the following composition:
Gm. Epsilon-aminocaproic acid 0.346 Sodium epsilon-aminocaproate 0.087 Lithium lactate 0.461 Nicotinamide-adenine dinucleotide (NAD) 0.048
Reagent B is prepared having the following composition:
Epsilon-aminocaproic acid 0.346 7 Sodium epsilon-aminocaproate 0.087 Lithium lactate 0.461
0.25 2,9-dimethyl-1,10-phenantl1roline 0.833 Neutronyx 0.50 Sulfuric acid 1 1.30
The addition of reagent C reduces the pH of the solutions to 3.2. The reaction mixtures are kept at 37 C. for 12 minutes.
The optical density of each of the reaction mixtures is read using a spectrophotometer set at wavelength 455 mg.
The units of lactate dehydrogenase per milliliter are read from a calibration curve prepared in accordance with the procedure set out in Example II.
EXAMPLE II Preparation of calibrati n curve for use in lactate dehydrogenase activity determination For the determination of the lactate dehydrogenase activity of serum, a calibration curve must be prepared using known concentrations of enzyme. Enzyme activities are expressed in terms of a lactate dehydrogenase unit defined as the amount of enzyme which catalyzes the conversion 'of one micromole NAD'to one micromole of NADH per 4 minute during the initial stage of the reaction carried out in the presence of very high concentrations of DL- lactate and NAD at pH 10.0 and 25 C. in a 0.1 M glycine-sodium glycinate butter.
A series of solutions of known concentrations of lactate dehydrogenase activity are prepared from a lyophilized preparation of dialyzed human plasma having an elevated lactate dehydrogenase activity. Each of the solutions is assayed according to the following procedure.-
At zero time, 0.10 ml. of enzyme solution is mixed with 5.0 ml. of buffered substrate solution having a temperature of 37 C. The buffered substrate solution contains 0.15 M DL-lactate, 0.0021 M NAD, and 0.1 M epsilon- Enzyme concentration, Measured units per ml.: absorbance EXAMPLE III Malate dehydrogenase At zero time 0.2 ml. of enzyme solution is mixed with 5.0 ml. of buffered substrate solution having a temperature of 37 C. The buffered substrate solution contains 0.10 M DL-malate, 0.002 M NAD and 0.10 M epsilonaminocaproate buffer. The substrate solution has a pH of 10.0. The mixture is incubated for 12 minutes at 37 C. The NADH formed is determined by mixing 1.0 ml. of the incubation mixture with 4.0 ml. of solution containing 0.25 M acetic acid, 0.175 M sodium acetate, 0.115 N sulfuric acid, 0.0005 M cupric sulfate and 0.002 M 2,9- dimethyl-l,10-phenanthroline. After fifteen minutes, the absorbance of the solution is measured at 455 m against a blank prepared in an identical manner, except that the NAD is omitted from the buffered substrate. solution.
The assay of varying amounts of crystalline malic dehydrogenase give the following results:
Absorbance Enzyme per test, g; at 455 mp 0 0.025 0.09 03108 0.19 0.179 0.28 0.260 0.46 0.420.
EXAMPLE 1V Alcohol dehydrogenase the incubation mixture with 4.0 ml. of solution containing 0.25 M acetic acid, 0.175 M sodium acetate, 0.115 N sulfuric acid, 0.0005 M cupric sulfate and 0.002 M 2,9
dimethyl-l,IO-phenanthrdline. The mixture is permitted to stand for 15 minutes and the absorbance of the solution is measured at 455 ru against a blank prepared in the identical manner, except that the NAD is omitted from '7 and assayed to give the following results:
Absorbance Enzyme per test, ,ug.: at 455 m 0 0.007 0.52 0.062 1.04 0.143 1.56 0.186 2.08 0.238 2.60 0.321
EXAMPLE V Isocz'trate delzydrogenase At zero time 0.2 ml. of enzyme solution is mixed with 2.8 ml. of buffered substrate solution containing 0.0035 M trisodium isocitrate, 0.15 M sodium chloride, 0.0017 M manganese chloride, 0.0018 M NADP and 0.054 M tris (hydroxymethyl)-aminomethane. The pH of the solution is 7.5. The mixture is incubated at 37 C. for 12 minutes. The NADPI-I formed is determined by the addition of 3.0 ml. of a solution containing 0.23 N surfuric acid, 0.001 M cupric sulfate and 0.004 M 2,9-dimethyl-l,l0- phenanthroline. The mixture is allowed to stand for 12 minutes at 37 C. and the absorbance is measured at 455 m against a blank prepared in the identical manner except that the NADP is omitted from the buffered substrate solution.
Aliquots of a human liver homogenate diluted with serum are assayed for isocitr-ate dehydrogenase activity with the following results:
Relative concentration Absorbance homogenate: at 455 m While the foregoing examples illustrate the use of the cupric chelate of 2,9-dimethyl-1,10-phenanthroline as the reducible color developing metal chelate, the reduction of other reducible color developing metal chelates 'by reduced nicotinamide-adenine 'dinucleotide (NADH are illustrated in the following examples:
Example VI Example VII A 0.2 ml. aliquot of an aqueos solution 0.01 M in the ferric chelate of 1,10-phenanthroline is added to 4.5 ml. of 0.5 M acetate bufier, pH 4.0. This solution is mixed with 0.5 ml. of a solution containing 1.74 M NADH and the absorbance of the resulting mixture is recorded at 510 my, the absorption maximum of ferrous 1,10-phenanthroline. A maximum absorbance of 0.351 was recorded after 30 min.
6 Example VIII A 0.2 ml. aliquot of an aqueous solution 0.01 M in the ferric chelate of sulfonated 4,7-diphenyl-1,10-phenanthroline was added to 4.5 ml. of 0.5 M acetate butter, pH 4.0. This solution was mixed with 0.5 ml. of a solution containing 1.74 10- M NADH and the absorbance of the resulting mixture was recorded at 525 m the absorption maximum of the ferrous chelate of sulfonated 4,7-diphenyl-1,10-phenanthroline. A maximum absorbance of 0.611 was recorded after 24 min.
Example IX A 0.2 ml. aliquot of an aqueous solution 0.01M in the cupric chelate of 2,9-dimethyl-4,7-diphenyl-1,10-phenanthroline is added to 4.5 ml. of 0.5 M acetate bufiier, pH 4.0. This solution is mixed with 0.5 ml. of a solution containing 1.74 10- M NADH and the absorbance of the resulting mixture is recorded at 480 my, the absorption maximum of the cu-prous chelate of 2,9-dimethyl-4,7-diphenyl-l,10-phenanthroline. A maximum absorbance of 0.400 is recorded after 15 min.
What is claimed is:
1. A method of determining the concentration in body fluid of nicotinamide-adenine nucleotide dependent enzymes which comprises incubating in a small volume of body fluid a buffered reduced substrate selected from the group consisting of lactic acid and lactic acid salts, malic acid and malic acid salts, a-hydroxybutyric acid and ahydroxybutyric acid salts, sorbitol, isocitric acid and isocitric acid salts and ethanol, and an oxidized coenzyme selected from the group consisting of nicotinamide-adenine dinucleotide and nicotinamide-adenine dinucleotide phosphate and a divalent cation, reducing the pH of the reaction mixture to a pH between about 2.8 and about 5.0 and adding a reducible color developing metal chelate selected from the group consisting of ferri chelates of 1,10-phenanthroline, 4,7-di'phenyl- 1,10-phenanthroline and sulfonated 4,7-diphenyl-l,l0- phenanthroline and cupric chelates of 2,9-dimethyl-1,10- phenanthroline and sulfonated 2,9-dimethyl-4,7-diphenyl-LIO-phenanthroline.
2. A method according to claim 1 of determining the concentration in body fluid of lactate dehydrogenase wherein the substrate is selected from the group consisting of lactic acid and lactic acid salts.
3. A method according to claim 1 of determining the concentration in body fluid of malate dehydrogenase wherein the substrate is selected from the group consisting of malic acid and malic acid salts.
4. A method according to claim 1 of determining the concentration in body fluid of alcohol dehydrogenase wherein the substrate is ethanol.
5. A method according to claim 1 of deter-mining the concentration in body fluid of isocitrate dehydrogenase wherein the substrate is selected from the group consisting of isocitric acid and isocitric acid salts.
References Cited UNITED STATES PATENTS 2,996,436 8/1961 Broida et a1 l103.5 2,999,052 9/1961 Albaum et a1 -103.5
OTHER REFERENCES Colowick et al.: Methods in Enzymology, vol. I, pp. 348, 349, 495, 496, 699, 700, 710 to 714 and 735 to 740 (1955).
Wilkinson: An Introduction to Diagnostic Enzymology, Edward Arnold PubL, London, pp. 9-12, 143-146, 165, 166, 169 to 172, 273 and 274 (1962).
A. LOUIS MONACELL, Primary Examiner. ALVIN E. TANENHOLTZ, Assistant Examiner.

Claims (1)

1. A METHOD OF DETERMINING THE CONCENTRATION IN BODY FLUID OF NICOTINAMIDE-ADENINE NUCLEOTIDE DEPENDENT ENZYMES WHICH COMPRISES INCUBATING IN A SMALL VOLUME OF BODY FLUID A BUFFERED REDUCED SUBSTRATE SELECTED FROM THE GROUP CONSISTING OF LACTIC ACID AND LACTIC ACID SALTS, MALIC ACID AND MALIC ACID SALTS, A-HYDROXYBUTYRIC ACID AND AHYDROXYBUTYRIC ACID SALTS, SORBITOL, ISOCITRIC ACID AND ISOCITRIC ACID SALS AND ETHANOL, AND AN OXIDIZED COENZYME SELECTED FROM THE GROUP CONSISTING OF NICOTINAMIDE-ADENINE INUCLEOTIDE-ADENINE DINUCLEOTIDE PHOSPHATE AND A DIVALENT CATION, REDUCING THE PH OF THE REACTION MIXTURE TO A PH BETWEEN ABOUT 2.8 AND ABOUT 5.0 AND ADDING A REDUCIBLE CLOR DEVELOPING METAL CHELATE SELECTED FROM THE GROUP CONSISTING OF FERRI CHELATES OF 1.10-PHENANTHROLINE, 4,7-DIPHENYL1,1.0-PHENANTHROLINE AND SULFONATED 4,7-DIPHENYL-1,10PHENANTHROLINE AND CUPRIC CHELATES OF 2.9-DIMETHYL-1,10PHENANTHROLINE AND SULFONATED 2,9-DIMETHYL-4,7-DIPHENYL-1,10-PHENANTHROLINE.
US555690A 1966-06-07 1966-06-07 Determination of dehydrogenase Expired - Lifetime US3331752A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US555690A US3331752A (en) 1966-06-07 1966-06-07 Determination of dehydrogenase

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US555690A US3331752A (en) 1966-06-07 1966-06-07 Determination of dehydrogenase

Publications (1)

Publication Number Publication Date
US3331752A true US3331752A (en) 1967-07-18

Family

ID=24218246

Family Applications (1)

Application Number Title Priority Date Filing Date
US555690A Expired - Lifetime US3331752A (en) 1966-06-07 1966-06-07 Determination of dehydrogenase

Country Status (1)

Country Link
US (1) US3331752A (en)

Cited By (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3493466A (en) * 1965-05-11 1970-02-03 Chugai Pharmaceutical Co Ltd Method and preparation for clinical diagnosis
US3539026A (en) * 1969-04-07 1970-11-10 Wayne N Sutliff Fishing tool energizer
FR2411411A1 (en) * 1977-12-07 1979-07-06 American Monitor Corp METHOD OF DETERMINING TRIGLYCERIDES IN A BIOLOGICAL FLUID
US4278760A (en) * 1978-08-01 1981-07-14 Boehringer Mannheim Gmbh Method and composition for determining an oxidized pyridine co-enzyme
US4701420A (en) * 1985-04-01 1987-10-20 Eastman Kodak Company Analytical compositions, elements and methods utilizing reduction of ferric ion chelates to form detectable dyes
US4742001A (en) * 1985-04-26 1988-05-03 Oriental Yeast Co. Ltd. Method of terminating isocitrate dehydrogenase reaction in an analytical system
US5141855A (en) * 1986-07-28 1992-08-25 Eastman Kodak Company Signal amplifying cobalt (III) redox reagents and methods for the determination of analytes in aqueous fluids
US6162615A (en) * 1995-11-22 2000-12-19 Roche Diagnostics Gmbh Stabilized coenzyme solutions and their use thereof for the determination of dehydrogenases or the substrate thereof in an alkaline medium
CN101324630A (en) * 2007-06-13 2008-12-17 苏州艾杰生物科技有限公司 Method for determining ethyl hydrate concentration ethyl hydrate diagnosis reagent kit

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2996436A (en) * 1958-06-02 1961-08-15 Sigma Chem Co Process for the colorimetric determination of lactic dehydrogenase
US2999052A (en) * 1959-03-16 1961-09-05 Miles Lab Composition for colorimetric test for serum enzymes

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2996436A (en) * 1958-06-02 1961-08-15 Sigma Chem Co Process for the colorimetric determination of lactic dehydrogenase
US2999052A (en) * 1959-03-16 1961-09-05 Miles Lab Composition for colorimetric test for serum enzymes

Cited By (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3493466A (en) * 1965-05-11 1970-02-03 Chugai Pharmaceutical Co Ltd Method and preparation for clinical diagnosis
US3539026A (en) * 1969-04-07 1970-11-10 Wayne N Sutliff Fishing tool energizer
FR2411411A1 (en) * 1977-12-07 1979-07-06 American Monitor Corp METHOD OF DETERMINING TRIGLYCERIDES IN A BIOLOGICAL FLUID
US4245041A (en) * 1977-12-07 1981-01-13 American Monitor Corporation Triglycerides assay and reagents therefor
US4278760A (en) * 1978-08-01 1981-07-14 Boehringer Mannheim Gmbh Method and composition for determining an oxidized pyridine co-enzyme
US4701420A (en) * 1985-04-01 1987-10-20 Eastman Kodak Company Analytical compositions, elements and methods utilizing reduction of ferric ion chelates to form detectable dyes
US4742001A (en) * 1985-04-26 1988-05-03 Oriental Yeast Co. Ltd. Method of terminating isocitrate dehydrogenase reaction in an analytical system
US5141855A (en) * 1986-07-28 1992-08-25 Eastman Kodak Company Signal amplifying cobalt (III) redox reagents and methods for the determination of analytes in aqueous fluids
US6162615A (en) * 1995-11-22 2000-12-19 Roche Diagnostics Gmbh Stabilized coenzyme solutions and their use thereof for the determination of dehydrogenases or the substrate thereof in an alkaline medium
CN101324630A (en) * 2007-06-13 2008-12-17 苏州艾杰生物科技有限公司 Method for determining ethyl hydrate concentration ethyl hydrate diagnosis reagent kit

Similar Documents

Publication Publication Date Title
Allred et al. Determination of coenzyme A and acetyl CoA in tissue extracts
US4743561A (en) Luminescent assay with a reagent to alter transmitive properties of assay solution
CA1125151A (en) Triglycerides assay and reagents therefor
Babson et al. Kinetic colorimetric measurement of serum lactate dehydrogenase activity
US4543326A (en) Stabilization of oxidase
US4495293A (en) Fluorometric assay
US4242446A (en) Method for determining a substance in a biological fluid and reagent combination for use in the method
US4251629A (en) Determination of hydrogen peroxide
EP0072581B1 (en) The stabilization of working reagent solutions containing enzymes, and the use of such stabilized reagents in enzyme or substrate assays
JPS61146196A (en) Method and reagent for improving photometry of h202
Berti et al. Enzymatic colorimetric method for the determination of inorganic phosphorus in serum and urine
JPH0470000B2 (en)
US4547461A (en) Composition, analytical element and method for the quantification of creatine kinase
Kasidas et al. A new enzymatic method for the determination of glycollate in urine and plasma
US3331752A (en) Determination of dehydrogenase
US4592996A (en) Process for determining reduced form coenzymes
US4271265A (en) Method and reagent for the determination of glutamate-oxalacetate transaminase and glutamate-pyruvate transaminase
US4241179A (en) Method for determining a transaminase in a biological fluid and reagent combination for use in the method
CN114966025B (en) Glutathione reductase assay kit and its preparation method and application
US5460948A (en) Assay of salicylates or reduced pyridine nucleotides
US3349006A (en) Process and composition for the enzymatic determination of uric acid
EP0570588B1 (en) Method and reagent for determination of serum iron or unsaturated iron binding capacity using aconitase
KINOSHITA et al. A fluorophotometric determination of serum creatinine and creatine using a creatinineamidohydrolase-creatineamidinohydrolase-sarcosine oxidase-peroxidase system and diacetyldichlorofluorescin
US3823071A (en) Prostatic acid phosphatase determination
EP0193204B1 (en) Process for determining superoxide dismutase activity